RxDoctor Payments Data

Leonard Buccellato, MD

Pulmonary Disease · Munster, INNPI 1437198348

Payments from drug & device makers

$2,197in general payments, 2019–2025

Across 142 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$284
  • AstraZeneca$220
  • Bayer$182
  • Johnson & Johnson$170
  • Teva Pharmaceuticals USA, Inc.$147
  • Boehringer Ingelheim$143
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,18299%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,197 in reported general payments places this provider in the 45th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$4,836
Medicare patients
17
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate34$427,715
Spiriva RespimatTiotropium Bromide413$323,084
BreynaBudesonide/Formoterol Fumarate341$138,853
Stiolto RespimatTiotropium Br/Olodaterol Hcl100$84,242
AlvescoCiclesonide211$56,621
Wixela InhubFluticasone Propion/Salmeterol183$54,339
Advair HfaFluticasone Propion/Salmeterol66$52,679
Pirfenidone159$37,530
Albuterol Sulfate HfaAlbuterol Sulfate513$14,604
Combivent RespimatIpratropium/Albuterol Sulfate22$13,708
Mycophenolate Mofetil44$7,286
Levalbuterol Tartrate HfaLevalbuterol Tartrate62$6,693
Fluticasone Propionate90$3,930
Octreotide Acetate13$3,869
Mycophenolic AcidMycophenolate Sodium18$3,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$143$848,749569 claims
Teva Pharmaceuticals USA, Inc.Proair Respiclick$147$1,33613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →